Clinical and microbiologic effects of subgingivally delivered 0.5% azithromycin in the treatment of chronic periodontitis

Journal of Periodontology

Volumn 79, Issue 11, 2008, Pages 2125-2135

  Pradeep, A R ^a   Sagar, S Vidya ^a   Daisy, Happy ^a  

^a Government Dental College and Hospital   (India)

Author keywords

Azithromycin; Dental scaling; Drug delivery; High performance liquid chromatography; Periodontitis; Root planing

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN;

ADULT; ARTICLE; BACTERIAL COUNT; CHRONIC PERIODONTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DRUG EFFECT; FOLLOW UP; GEL; GINGIVITIS; HUMAN; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERIODONTICS; PERIODONTITIS; PREVENTIVE DENTISTRY; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHRONIC PERIODONTITIS; COLONY COUNT, MICROBIAL; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DENTAL SCALING; FOLLOW-UP STUDIES; GELS; GINGIVAL CREVICULAR FLUID; HUMANS; MIDDLE AGED; PERIODONTAL INDEX; PERIODONTAL POCKET; TREATMENT OUTCOME;

EID: 55749092298     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2008.070589     Document Type: Article

References (68)

1. Slots J. The search for effective, safe and affordable periodontal therapy. Periodontol 2000 2002;28:9-11.
2. Slots J. Subgingival microflora and periodontal disease. J Clin Periodontol 1979;6:351-352.
3. Moore WEC. Microbiology of periodontal disease. J Periodontal Res 1987;22:335-341.
4. Socransky SS, Haffajee AD. Dental biofilms: Difficult therapeutic targets. Periodontol 2000 2002;28:12-55.
5. Steinberg D, Friedman M, Soskolne A, Sela MN. A new degradable controlled release device for treatment of periodontal disease: In vitro release study. J Periodontol 1990;61:393-398.
6. Rabbani GM, Ash MM Jr., Caffesse RG. The effectiveness of sub-gingival scaling and root planing in calculus removal. J Periodontol 1981;52:119-123.
7. Herrera D, Sanz M, Jepsen S, Needleman I, Roldan S. A systematic reviewonthe effect of systemic antimicrobials as an adjunct to scaling and root planing in periodontitis patients. J Clin Periodontol 2002;29(Suppl. 3):136-159.
8. Jorgensen MG, Slots J. Responsible use of antimicrobials in periodontics. J Calif Dent Assoc 2000;28:185-193.
9. Greenstein G, Polson A. The role of local drug delivery in the management of periodontal disease: A comprehensive review. J Periodontol 1998;69:507-520.
10. Greenstein G. Clinical significance of bacterial resistance to tetracyclines in the treatment of periodontal diseases. J Periodontol 1995;66:925-932.
11. McDonald PJ, Pruul H. Phagocytic uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991;10:828-833.
12. Schentag JJ, Ballow CH. Tissue directed pharmacokinetics. Am J Med 1991;91:5S-11S.
13. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl. A):73-82.
14. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-282.
15. Williams JD, Maskell JP, Shain H. Comparative in vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms. J Antimicrob Chemother 1992;30:27-37.
16. Peters DH, Friedel HA, McTavish D. Azithromycin: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44:750-799.
17. Pajukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1992;36:1241-1243.
18. Pajukanta R. In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol 1993;8:325-326.
19. Filatova NA, Kuznetsov EA, Dmitrieva LA, Tsarev VN, Kalinin AI. The prospects for using the new macrolide antibiotic azithromycin (Sumamed) in combined treatment of periodontitis (in Russian). Stomatologiia (Mosk) 1995;74:12-15.
20. van Winkelhoff AJ, Herrera D, Winkel EG, Dellemijn-Kippuw N, Vandenbroucke-Grauls CM, Sanz M. Antibiotic resistance in subgingival microflora in patients with adult periodontitis. A comparative survey between Spain and the Netherlands (in Dutch). Ned Tijdschr Tandheelkd 1999;106:290-294.
21. Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002;450:277-289.
22. Blandizzi C, Malizia T, Lupetti A, et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol 1999;70:960-966.
23. Smith SR, Foyle DM, Daniels J, et al. A double-blind placebo-controlled trial of azithromycin as an adjunct to non-surgical treatment of periodontitis in adults: Clinical results. J Clin Periodontol 2002;29:54-61.
24. Haffajee AD, Torresyap G, Socransky SS. Clinical changes following four different periodontal therapies for the treatment of chronic periodontitis: 1 year results. J Clin Periodontol 2007;34:243-253.
25. Gilding DK, Reed AM. Biodegradable polymers for use in surgery-polyglycolic/polylactic acid homo- and copolymers: 1. Polymer 1979;20:1459-1464.
26. Kobayashi H, Shiraki K, Ikada Y. Toxicity test of biodegradable polymers by implantation in rabbit cornea. J Biomed Mater Res 1992;26:1463-1476.
27. Meikle MC, Papaioannou S, Ratledge TJ, et al. Effect of poly DL-lactide-co-glycolide implants and xenogeneic bone matrix-derived growth factors on calvarial bone repair in the rabbit. Biomaterials 1994;15:513-521.
28. Miyamoto H, Ogura Y, Hashizoe M, Kunou N, Honda Y, Ikada Y. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr Eye Res 1997;16:930-935.
29. Wagenaar BW, Muller BW. Piroxicam release from spray-dried biodegradable microspheres. Biomaterials 1994;15:49-54.
30. Benoit MA, Mousset B, Delloye C, Bouillet R, Gillard J. Antibiotic-loaded plaster of Paris implants coated with poly lactide-co-glycolide as a controlled release delivery system for the treatment of bone infections. Int Orthop 1997;21:403-408.
31. Calhoun JH, Mader JT. Treatment of osteomyelitis with a biodegradable antibiotic implant. Clin Orthop 1997;341:206-214.
32. Jacob E, Cierny G 3rd, Zorn K, McNeill JF, Fallon MT. Delayed local treatment of rabbit tibial fractures with biodegradable cefazolin microspheres. Clin Orthop 1997;336:278-285.
33. Jacob E, Setterstrom JA, Bach DE, Heath JR 3rd, McNiesh LM, Cierny G 3rd. Evaluation of biodegradable ampicillin anhydrate microcapsules for local treatment of experimental staphylococcal osteomyelitis. Clin Orthop 1991;267:237-244.
34. Kageruka P, Kabore H, Marcotty T, et al. Comparative evaluation of the prophylactic effect of slow release devices containing homidium bromide and sometamidium on Trypanosoma congolense in rabbits. Vet Parasitol 1996;63:179-185.
35. Nie L, Nicolau DP, Nightingale CH, Browner BD, Quintiliani R. In vitro elution of ofloxacin from a bioabsorbable polymer. Acta Orthop Scand 1995;66:365-368.
36. Hashizoe M, Ogura Y, Kimura H, et al. Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch Ophthalmol 1994;112:1380-1384.
37. Mason N, Thies C, Cicero TJ. In vivo and in vitro evaluation of a microencapsulated narcotic antagonist. J Pharm Sci 1976;65:847-850.
38. Yolles S, Leafe TD, Woodland JH, Meyer FJ. Long acting delivery systems for narcotic antagonists II: Release rates of naltrexone from poly (lactic acid) composites. J Pharm Sci 1975;64:348-349.
39. Craig PH, Williams JA, Davis KW, et al. A biologic comparison of polyglactin 910 and polyglycolic acid synthetic absorbable sutures. Surg Gynecol Obstet 1975;141:1-10.
40. Asano M, Fukuzaki H, Yoshida M, et al. In vivo characteristics of low molecular weight copoly (D, L-lactic acid) formulations with controlled release of LH-RH agonist. Biomaterials 1989;10:569-573.
41. Nakamura T, Hitomi S, Watanabe S, Shimiz Y, Hyon SH, Ikada Y. Bioabsorption of polylactides with different molecular properties. J Biomed Mater Res 1989;23:1115-1130.
42. Vandorpe J, Schacht E, Dunn S, et al. Long circulating biodegradable poly(phosphazene) nanoparticles surface modified with poly(phosphazene)- poly(ethylene oxide) copolymer. Biomaterials 1997;18:1147-1152.
43. Lobene RR, Weatherford T, Ross NM, Lamm RA, Menaker L. A modified gingival index for use in clinical trials. Clin Prev Dent 1986;8:3-6.
44. Mombelli A, van Oosten MA, Schurch E, Lang NP. The microbiota associated with successful or failing implants. Oral Microbiol Immunol 1987;2:145-151.
45. Greenwell H, Bissada NF. Variations in subgingival microflora from healthy and intervention sites using probing depth and bacteriological identification criteria. J Periodontol 1984;55:391-397.
46. Shah NH, Railkar AS, Chen FC, Tarantino R, Kumar S, Murjani M. A biodegradable injectable implant for delivering micro and macromolecules using poly (lactic coglycolic) acid (PLGA) copolymers. J Control Rel 1993;27:139-147.
47. Goodson JM, Hogan PE, Dunham SL. Clinical responses following periodontal treatment by local drug delivery. J Periodontol 1985;56(Spec. Issue):81-87.
48. Needleman IG, Pandya NV, Smith SR, Foyle DM. The role of antibiotics in the treatment of periodontitis (Part 2 - Controlled drug delivery). Eur J Prosthodont Restor Dent 1995;3:111-117.
49. Kornman KS. Controlled release of local delivery of antimicrobials in periodontics - Prospects for the future. J Periodontol 1993;64:782-791.
50. Gomi K, Yashima A, Iino F, et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol 2007;78:918-923.
51. Gomi K, Yashima A, Nagano T, Kanazashi M, Maeda N, Arai T. Effects of full mouth scaling and root planing in conjunction with systemically administered azithromycin. J Periodontol 2007;78:422-429.
52. Sefton AM, Maskell JP, Beighton D, Whiley A, Shain H, Foyle D. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol 1996;23:998-1003.
53. Tsarev VN, Dmitrieva LA, Filatova NA, Romanov AE, Chekhova NO. A trial of the use of rulid, sumamed and makropen in the combined treatment of generalized periodontitis at a stage of exacerbation (in Russian). Stomatologiia (Mosk) 1997;76:4-8.
54. Mascarenhas P, Gapski R, Al-Shammari K, et al. Clinical response of azithromycin as an adjunct to non-surgical periodontal therapy in smokers. J Periodontol 2005;76:426-436.
55. Dastoor SF, Travan S, Neiva RF, Rayburn LA, Giannobile WV, Wang HL. Effect of adjunctive azithromycin with periodontal surgery in the treatment of chronic periodontitis in smokers: A pilot study. J Periodontol 2007;78:1887-1896.
56. McHugh RC, Rice A, Sangha ND, et al. A topical azithromycin preparation for the treatment of acne vulgaris and rosacea. J Dermatolog Treat 2004;15:295-302.
57. Kuehne JJ, Yu AL, Holland GN, et al. Corneal pharmacokinetics of topically applied azithromycin and clarithromycin. Am J Ophthalmol 2004;138:547-553.
58. Langer R. New method of drug delivery. Science 1990;249:1527-1533.
59. Robert P, Mauduit J, Frank RM, Vert M. Biocompatibility and resorbability of a polylactic membrane for periodontal guided tissue regeneration. Biomaterials 1993;14:353-358.
60. Maze GI, Reinhardt RA, Agarwal RK, et al. Response to intracrevicular controlled delivery of 25% tetracycline from poly(lactide/glycolide) film strips in SPT patients. J Clin Periodontol 1995;22:860-867.
61. Kurtis B, Unsal B, Centiner D, et al. Effect of polylactide/ glycolide (PLGA) membranes loaded with metronidazole on periodontal regeneration following guided tissue regeneration in dogs. J Periodontol 2002;73:694-700.
62. Soskolne WA, Heasman PA, Stabholz A, et al. Sustained local delivery of chlorhexidine in the treatment of periodontitis: A multi-center study. J Periodontol 1997;68:32-38.
63. Kinane DF, Radavar M. A six-month comparison of three periodontal local antimicrobial therapies in persistent periodontal pockets. J Periodontol 1999;70:1-7.
64. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical application of polylactic acid/polyglycolic acid copolymers. Biomaterials 1996;17:93-102.
65. Taylor MS, Daniels AU, Andriano KP, Heller J. Six bioabsorbable polymers: In vitro acute toxicity of accumulated degradation products. J Appl Biomater 1994;5:151-157.
66. van Sliedregt A, van Loon JA, van Der Brink J, de Groot K, van Blitterswijk CA. Evaluation of polylactide monomers in an in vitro biocompatibility assay. Biomaterials 1994;15:251-256.
67. Brown M, Gilbert P. Sensitivity of biofilms to antimicrobial agents. J Appl Bacteriol 1993;74:87s-97s.
68. Wilson M. Susceptibility of oral bacterial biofilms to antimicrobial agents. J Med Microbiol 1996;44:79-87.